In a webinar series designed for healthcare providers, the TAA has identified topics that are applicable to those who are involved in the care of individuals living with Tourette Syndrome and for those who are interested in learning more about TS treatment and management. We invite physicians, nurses, nurse practitioners, and psychologists, regardless of Tourette Syndrome experience, to participate in these webinars.
Each webinar will be accredited for CMEs; more information will be provided soon.
*All times are in Eastern Standard time*
Identification and Management of ADHD and Impulse Control in Tourette Syndrome
Tuesday, March 9, 2021 3–4 pm EST
Attention Deficit Disorder, either the inattentive, hyperactive, or combined type is fairly common in patients with Tourette syndrome. Furthermore, impulse control disorders are common as well. Frequently, the functional impact of these conditions outweighs the impact of tics in the lives of these patients. This webinar will define both disorders and explore best ways to manage them in children and adults with Tourette Syndrome.
- To define ways ADHD can present and impact patients with Tourette syndrome
- To define ways impulse control can present and impact the lives of patients with Tourette syndrome
- To delineate the different treatments, whether behavioral, lifestyle or pharmacological, to manage both conditions.
Speaker: Dr. Katie Kompoliti
Dr. Katie Kompoliti
Professor, Department of Neurological Sciences
Education Director, Section of Movement Disorders Department of Neurological Sciences
Rush University Medical Center
Aikaterini Kompoliti, MD, was born in Greece and completed her early education there, including medical school. After graduating from the University of Patras Medical School, Greece, she pursued her interest in neuroscience by completing a residency in neurology at Northwestern University, Chicago, followed by a fellowship in movement disorders at Rush University Medical Center, Chicago. After the completion of her fellowship, she became a faculty member in movement disorders in the Department of Neurological Sciences at Rush University Medical Center where she is currently professor of neurology. She is the author and co-author of numerous publications. Her clinical interests as a principal investigator in research have focused on several therapeutic areas including studies to evaluate the safety and efficacy of new compounds to treat Parkinson’s disease, Tourette’s syndrome, functional movement disorders and dystonia. Furthermore, she is the educational director of the section of movement disorders and the director of the movement disorders fellowship at Rush University Medical Center. Dr. Kompoliti is the director of a Center of Excellence on Tourette syndrome and Tic Disorders at Rush University Medical Center.
Refractory Tourette Syndrome
Thursday, April 8 TIME TBD
Achieving an effective treatment strategy for Tourette syndrome (TS) can be challenging in some cases, especially when associated co-morbidities or psychosocial factors influence disease manifestations. Since there is no current consensus on the definition of “refractory” TS, a framework of understanding “refractoriness” will be presented, including considerations related to proper diagnosis, symptom assessment, therapy dosing, adherence or side effects, and impact of co-occurring conditions and environmental influences. This case-based presentation will explore courses of action for clinicians to consider when symptom treatments in TS do not respond sufficiently to usual approaches.
- List factors that can contribute to poor response to treatment interventions in TS
- Assess relevant symptom severity relating to tics and co-morbidities
- Describe potential modifications to the treatment strategy when symptoms in TS do not respond sufficiently to usual approaches
Speaker: Dr. Joohi Jimenez-Shahed
Dr. Joohi Jimenez-Shahed
Associate Professor of Neurology, Movement Disorders and Neurosurgery
Ichan School of Medicine, Mount Sinai
Dr. Jimenez-Shahed is an Associate Professor of Neurology and Medical Director, Movement Disorders Neuromodulation and Brain Circuit Therapeutics at the Icahn School of Medicine at Mount Sinai. After completing her undergraduate degree at Washington University in St. Louis, Dr. Jimenez-Shahed received her medical degree from Baylor College of Medicine (BCM) and Neurology residency training at Duke University Medical Center. She then completed a fellowship in Movement Disorders at the Parkinson’s Disease Center and Movement Disorders Clinical (PDCMDC) at BCM. Her research interests lie in investigating the intraoperative neurophysiology of patients undergoing deep brain stimulation (DBS) for movement disorders.
Dr. Jimenez-Shahed serves as Chair of the Functional Neurosurgical Working Group of the Parkinson Study Group, and is the lead investigator for RAD-PD: a national quality improvement registry for patients undergoing DBS surgery for Parkinson’s disease. She is also an investigator with the Huntington Study Group, Dystonia Coalition and TSA International Database of DBS Studies in Tourette syndrome. She currently serves on the Science Advisory Board of the Davis Phinney Foundation and the Medical Advisory Board of the Tourette Association of America and has chaired the Medical Advisory Board for the Houston Area Parkinson Society. She has served as Principal Investigator for industry-sponsored and investigator-initiated clinical trials and has authored several papers and book chapters.
She is the recipient of the Roy H. Cullen Quality of Life Award (Houston Area Parkinson Society), the Rising Star Clinician Award (BCM), the Fulbright & Jaworski L.L.P. Faculty Excellence Award in Teaching and Evaluation (BCM) and the Healthcare Heroes Award for Outstanding Health Care Practitioner (Houston Business Journal). She was recognized as a Woman of Excellence at BCM and is a 2018 graduate of the inaugural Women Leading in Neurology program of the American Academy of Neurology.
Advances in the Treatment of Tics
Thursday, May 13, 2021 3 – 4pm EST
Motor and phonic tics associated with Tourette syndrome (TS) can range in severity from barely perceptible to disabling and most patients have a variety of behavioral co-morbidities, particularly, attention deficit disorder and obsessive-compulsive disorder. Therefore, therapy must be tailored to the individual needs of the patients. In addition to behavioral therapy, oral medications such as alpha agonists, dopamine depletors, anti-psychotics, and topiramate are used to control the involuntary movements and noises. Botulinum toxin injections are particularly effective in patients with troublesome focal motor and phonic tics, including coprolalia. Deep brain stimulation may be considered for patients with “malignant” TS, that is, refractory to medical therapy. When appropriate therapy is selected and implemented, most patients with TS can achieve their full potential and lead essentially normal life.
- To become familiar with the current therapeutic approach in patients with tics and Tourette syndrome.
- To understand the rationale for and basic pharmacology of novel drugs used in the treatment of Tourette syndrome.
- To learn about emerging medical and surgical treatments of tics.
Speaker: Dr. Joseph Jankovic
Dr. Joseph Jankovic
Professor of Neurology
Distinguished Chair in Movement Disorders Director, Parkinson’s Disease Center and Movement Disorders Clinic Director
Center of Excellence for Parkinson’s Foundation and Tourette Association of America
Baylor College of Medicine
Dr. Jankovic is a Professor of Neurology, Distinguished Chair in Movement Disorders, and Founder and Director of the Parkinson’s Disease Center and Movement Disorders Clinic (PDCMDC), Department of Neurology, Baylor College of Medicine, Houston, Texas. After completing his Neurology training at Columbia University, New York City, he joined the faculty of Baylor College of Medicine in 1977. Since that time he has led clinical team that focuses on the most compassionate and expert care and research on etiology, pathophysiology, and experimental therapeutics of Parkinson’s disease and related neurodegenerative and movement disorders such as tremors, dystonia, Tourette syndrome, Huntington disease, restless legs syndrome, tardive dyskinesia, and paroxysmal dyskinesias. Under the direction of Dr. Jankovic the PDCMDC has been recognized as “Center of Excellence” by the Parkinson’s Foundation, the Huntington Disease Society of America, the Tourette Association of America, and the Wilson Disease Association.
Past president of the International Parkinson and Movement Disorder Society and of the International Neurotoxin Association, Dr. Jankovic is the recipient of many awards including the American Academy of Neurology (AAN) Movement Disorders Research Award, First National Parkinson Foundation Distinguished Service Award, Huntington’s Disease Society of America Guthrie Family Humanitarian Award, Tourette Syndrome Association Lifetime Achievement Award, Dystonia Medical Research Foundation Distinguished Service Award, Benign Essential Blepharospasm Research Foundation Award, and Lifetime Achievement Award from the International Neurotoxin Association, Dr. Jankovic has been recognized as an Honorary Member of the American Neurological Association, Australian Association of Neurologists, French Neurological Society, and the International Parkinson’s Disease and Movement Disorders Society.
Dr. Jankovic has published over 1,200 original articles and over 55 books, is included among “Highly Cited Researchers”, and has been ranked #1 expert in the world in movement disorders and in botulinum toxins (http://expertscape.com/).
He has served as the principal investigator in hundreds of clinical trials and his pioneering research on drugs for parkinsonian disorders and hyperkinetic movement disorders has led to their approval by the Food and Drug Administration. Certified by the American Board of Psychiatry and Neurology, Dr. Jankovic is a fellow of the AAN and current or past member of many scientific and medical advisory boards and has served on the executive scientific advisory boards of the Michael J. Fox Foundation for Parkinson’s Research and the National Parkinson Foundation. Dr. Jankovic has mentored numerous fellows and other trainees many of whom have become leaders in the field of neurology and movement disorders. For further information visit www.jankovic.org.
Transitioning to Adult Care: Time is Ticcing Away
Tuesday, July 13, 2021 from 3 – 4pm EST
In this webinar, we will discuss the process of transitioning from Pediatric to Adult care for patients with Tourette Syndrome, Chronic Tic Disorders, and co-occurring conditions. There are a number of dramatic contrasts between Pediatric and Adult medicine that often complicate transition process. For example, the dynamics of an adult medical visit are completely different than in a Pediatric medical visit. Also, coordination of care between medical providers is often more complicated and is more patient driven. Participants of this webinar will be presented with strategies to manage these and other challenges inherent to the transition process.
- At the end of this webinar, participants will be able to identify the hurdles that can impede successful transition to adult care and how to overcome them.
- At the end of this webinar, participants will be able to identify the significant contrasts between a Pediatric and Adult medical visit and use strategies to manage these contrasting models of care.
- At the end of this webinar, participants will be able to discuss how to advocate for themselves to facilitate effective care coordination between multiple medical providers.
Speaker: Dr. Keith Coffman
Dr. Keith Coffman
Director, Tourette Syndrome Center of Excellence
Director, Movement Disorders Clinic
Children’s Mercy Hospital Kansas City
Keith Coffman, M.D., is an Associate Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine. His clinical specialties include tics and Tourette Syndrome; movement disorders; developmental delay; neurodegenerative disorders and neurogenetic disorders. Dr. Coffman attended medical school at Pennsylvania State University College of Medicine and completed his Pediatrics and Neurodevelopmental Disabilities residencies at Children’s Hospital of Pittsburgh of UPMC. This was followed by a research fellowship in Systems Neuroscience at the University of Pittsburgh. His research focus is on the neuroanatomy of the cerebellar vermis and its role in motor control and higher cognitive function.
For previously recorded Provider Education webinars, check out the offerings below:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Warren Alpert Medical School of Brown University and the Tourette Association of America. The Warren Alpert Medical School of Brown University is accredited by the ACCME to provide continuing medical education for physicians.
Physicians: The Warren Alpert Medical School of Brown University designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants & Nurse Practitioners: Participants will receive a Certificate of Attendance stating this program is designated for 1.0 hours AMA PRA Category 1 CreditTM. This credit is accepted by the AAPA and AANP.
Method of Participation
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives, faculty information, and CME information prior to participating in the activity.
- View the CME presentations.
- Complete the CME activity evaluation at the conclusion of the activity, select desired credit type and then gain immediate access to your certificate.
Presenter: Dr. John Walkup
Description: This webinar was suitable for all providers who are interested in working with patients dealing with Tourette Syndrome.
Dr. John T. Walkup is Professor of Psychiatry, Northwestern Feinberg School of Medicine and Chair, the Department of Child and Adolescent Psychiatry, Ann and Robert H. Lurie Children’s Hospital of Chicago. He recently moved to Northwestern after being the Division Director of Child and Adolescent Psychiatry at Weill Cornell Medical College in New York City. He is also an Adjunct Professor in the Center for American Indian Health at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University School of Medicine.
Dr. Walkup is one of a very small and elite group of academic child and adolescent psychiatrists in the United States. His work covers three main areas of innovation and investigation. His work with movement disorders, specifically Tourette syndrome, uniquely spans psychiatry, child psychiatry and neurology. His expertise in child and adolescent psychiatry clinical trials focuses on the development and evaluation of psychopharmacological and psychosocial treatments and lastly, he has been involved in developing and evaluating interventions to reduce the large mental health disparities facing Native American youth, specifically drug use and suicide prevention. Over his career, Dr. Walkup has been awarded over $20 million in grants and contracts to support his research.
His capacity to apply research methodologies across numerous neuropsychiatric disorders and his extension of that skill to address mental health disparities in Native American youth make him a singularly unique contributor to psychiatry, neurology and public health.
For his work, he has been awarded three United States achievement awards for child and adolescent psychiatry, the Norbert and Charlotte Rieger Award for Academic Achievement in 2009 from the American Academy of Child and Adolescent Psychiatry, the Blanche F. Ittleson Award for Research in Child Psychiatry in 2011 from the American Psychiatric Association and the Schonfeld Award from the American Society of Adolescent Psychiatry in 2016.
A recent paper of his (Walkup JT. Antidepressant Efficacy for Depression in Children and Adolescents: Industry- and NIMH-Funded Studies. Am J Psychiatry. 2017 May 1;174(5):430-437 was considered by the editor of the American Journal of Psychiatry, Robert Freedman, MD, his choice for ‘Paper of the Year’. He has also served as a member of two National Academy (IOM) Committees on Developing Evidence-Based Standards for Psychosocial Interventions for Mental Disorders and Improving Health Outcomes for Children with Disabilities. He currently serves as a Counselor-at-Large for the American Academy of Child and Adolescent Psychiatry. He is also a Member of the Board of Director of the Tourette Association of America.
Presenter: Dr. Tamara Pringsheim
Description: Based upon the recently published American Academy of Neurology guidelines on the treatment of tics, this webinar will guide providers on the comprehensive evaluation of people with tics, including assessment of comorbid disorders. The evidence to support the use of behavioral therapies and pharmacological treatments for tics will be reviewed, with discussion of how to safely prescribe these interventions in clinical practice.
Dr. Tamara Pringsheim is an Associate Professor with the Department of Clinical Neurosciences, Psychiatry, Pediatrics and Community Health Sciences at the University of Calgary. She is the program lead for the Tourette and Pediatric Movement Disorder program at Alberta Children’s Hospital and the Deputy Director of the Mathison Centre for Mental Health Research and Education. She also works as an evidence-based medicine methodologist for the American Academy of Neurology.
Dr. Pringsheim completed her residency in neurology at the University of Toronto and a fellowship in movement disorders and neuropsychiatry at the Toronto Western Hospital, and her Master of Science in Clinical Epidemiology. Her research program is focused on rational pharmacotherapy for neurological and mental health disorders, using knowledge synthesis and translation strategies.
She has developed clinical practice guidelines and tools for clinicians, and nationally implemented educational curricula with the goal of improving the safety, effectiveness and appropriateness of care.
Presenters: Dr. Matthew Capriotti and Dr. Christine Conelea
Description: In this webinar, Dr. Matthew Capriotti and Dr. Christine Conelea, two CBIT experts, discussed and demonstrated keys to providing thoughtful, high-quality CBIT treatment to clients via telehealth. They briefly overviewed teletherapy basics, with specific considerations for providing teletherapy in the context of the COVID-19 crisis. They also demonstrated how to implement CBIT effectively over videoconferencing, commenting on specific adaptations and considerations for telehealth.
Dr. Matthew Capriotti is a licensed clinical psychologist and an Assistant Professor of Psychology at San José State University (SJSU). He holds his Ph.D. in psychology from the University of Wisconsin-Milwaukee (2015) and completed pre- and post-doctoral fellowships in the Department of Psychiatry at the University of California San Francisco (2014-2016). Recently, Dr. Capriotti recently conducted a clinical trial of in-home teleCBIT, funded by a Clinical Research Training Fellowship from the Tourette Association of America and the American Academy of Neurology. He also co-led the Treating Tourette Together project, which brought together people with Tourette Syndrome, their families, clinicians, researchers, and other stakeholders to set an agenda for the next generation of CBIT research. Over the last decade, Dr. Capriotti has published 31 scientific journal articles and 7 book chapters on Tourette Syndrome, obsessive-compulsive spectrum disorders, and on LGBTQ+ mental health.
Christine Conelea, Ph.D., is an assistant professor in the Department of Psychiatry and Behavioral Sciences at the University of Minnesota and a licensed psychologist. She received her doctorate in psychology from the University of Wisconsin-Milwaukee in 2011 and completed a fellowship in child mental health at the Alpert Medical School of Brown University in 2014. She has over 50 publications on the topics of tics, OCD, and anxiety, and her research in these areas has been funded by the NIH. Dr. Conelea currently co-directs the Converging Approaches to Neurodevelopment Lab, which focuses on using dimensional approaches to study the causes and treatment of neurodevelopmental disorders, including tic disorders, OCD, ADHD, and autism. She also studies dissemination of evidence-based treatments and strategies for integrating neuroscience and behavioral methods to improve mental health.
She has developed clinical practice guidelines and tools for clinicians, and nationally implemented educational curricula with the goal of improving the safety, effectiveness and appropriateness of care.